<?xml version='1.0' encoding='UTF-8'?><xml><records><record><source-app name="HighWire" version="7.x">Drupal-HighWire</source-app><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Nichols, Emma Hitt</style></author></authors><secondary-authors><author><style face="normal" font="default" size="100%">Boehncke, Wolf-Henning</style></author></secondary-authors></contributors><titles><title><style face="normal" font="default" size="100%">Evaluation for Comorbidities Important in Psoriasis</style></title><secondary-title><style face="normal" font="default" size="100%">MD Conference Express</style></secondary-title></titles><dates><year><style  face="normal" font="default" size="100%">2014</style></year><pub-dates><date><style  face="normal" font="default" size="100%">2014-11-01 00:00:00</style></date></pub-dates></dates><pages><style  face="normal" font="default" size="100%">17-19</style></pages><abstract><style  face="normal" font="default" size="100%">Patients with psoriasis are at an increased risk of developing multiple comorbidities, including psoriatic arthritis (PsA), cardiovascular disease, diabetes mellitus, and cancer. This article discusses the practical aspects of diagnosing and managing patients, cardiometabolic risk assessment in patients with psoriasis, as well as systemic comorbidities with psoriasis.</style></abstract><number><style face="normal" font="default" size="100%">37</style></number><volume><style face="normal" font="default" size="100%">14</style></volume></record></records></xml>